We specialise in Parkinson’s disease, motor neuron disease; MND (amyotrophic lateral sclerosis; ALS), Huntington's disease, and neuroinflammation assays.

  • Capacity in preclinical drug testing (efficacy) in disease models, or target validation studies.
  • Range of state-of-the-art disease models accepted by funders and regulators as best-practice preclinical efficacy models.
  • An extensive range of both standardised and novel behavioural and pathological analyses that can be customised to suit individual requirements.
  • Can be coupled with pharmacodynamic and pharmacokinetic data from the same animal to maximise data output and assay validation.
  • Successful record in completing industry contracts, with two drugs undergoing human clinical trials after successful testing in preclinical models.
  • Strong publication track record in preclinical neurodegenerative disease animal studies.
  • Offer opportunities for leverage funding through non-diluting grant funding.
  • Competitive rates for both fee-for-service or collaborative research projects.

In vivo models available

  • Neuroinflammation endotoxin model (peripheral or central induction)
  • Parkinson’s disease 6-hydroxydopamine (6-OHDA) model
  • Parkinson’s disease synuclein pre-formed fibril (PFF-Syn) model
  • Motor neuron disease SOD1G93A transgenic mouse model
  • Motor neuron disease TDP43-transgenic mouse models
  • Huntington’s disease R6/1 transgenic mouse model

In vitro/ex vivo models available

  • Primary human microglia neuroinflammation assays (derived from human blood)
  • Primary mouse microglia neuroinflammation assays (derived from mice CNS tissue)
  • Whole blood activation assays